UnitedHealthcare · Veozah Vms · US health-plan appeal rights

Veozah Vms denied as duplicate or overlapping therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Veozah Vms denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Prior Authorization — Veozah (Fezolinetant) for VMS

The UnitedHealthcare angle on Veozah Vms

## Why UHC May Deny Veozah for VMS as Duplicate Therapy

Veozah (fezolinetant) is an FDA-approved neurokinin 3 (NK3) receptor antagonist indicated for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. UnitedHealthcare's duplicate-therapy denial means their system identified another drug in the same therapeutic category — most often a hormone therapy (HT) or another non-hormonal treatment — already on file for you, and determined that two agents targeting VMS constitutes a duplication.

## Why This Is Appealable

Duplicate-therapy edits are algorithm-driven and frequently misfire when the concurrent drug is being used for a different indication, has failed or is being tapered, or when Veozah's distinct mechanism makes it clinically non-duplicative. Fezolinetant acts centrally on the thermoregulatory pathway via NK3 receptor blockade — a mechanism entirely separate from estrogen. If you cannot use hormone therapy (due to hormone-receptor-positive cancer history, cardiovascular risk, or personal preference) or if the concurrent drug is inadequate, a duplicate-therapy denial mischaracterizes the clinical situation.

## Federal Appeal Framework

Internal appeal: Submit under ACA/ERISA §503. Request the specific clinical review criteria UHC applied and the identity of the drug they consider duplicative.
Expedited review: Available if symptoms are severely impairing function or if delay would cause significant harm; decision required within 72 hours.
External review (ACA §2719): After final internal denial, you have approximately four months to request independent external review. An independent reviewer evaluates whether the clinical distinction between Veozah and the supposedly duplicative drug justifies separate authorization.

## Documentation to Gather

1. Diagnosis confirmation: Documentation of menopause diagnosis and characterization of VMS frequency and severity from the clinical record. 2. Identification of the alleged duplicate: Clarify from UHC which drug triggered the edit, then document the distinct indication, mechanism, or status of that drug. 3. Hormone therapy contraindication or failure history: If HT is contraindicated (with clinical rationale) or was tried and was inadequate, document dates and outcomes. 4. Prescriber letter distinguishing Veozah: The prescriber should explain fezolinetant's non-hormonal mechanism, why the concurrent (or prior) agent does not address the same pathway, and why combination or substitution is clinically inappropriate. 5. Applicable guideline support: Reference the relevant professional society guideline (e.g., NAMS — the Menopause Society) on non-hormonal options for VMS in patients who cannot use HT.

## Criteria-Mapping Structure for Your Appeal Letter

| UHC Duplicate-Therapy Criterion | Your Clinical Response | |---|---| | Drug identified as duplicate | Name the alleged duplicate; explain distinct mechanism or indication | | Patient cannot use or failed the listed agent | Document contraindication or failure with dates | | Veozah is not interchangeable with the listed agent | Prescriber explanation of NK3 mechanism vs. the other drug's mechanism | | Clinical necessity for Veozah specifically | Severity of VMS; impact on daily function; why this drug is appropriate |

Provide this mapping in the appeal letter so the reviewer can address the duplicate-therapy flag point by point.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Veozah Vms

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.